The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy

Status unconfirmed

Conditions studied: Muscular Dystrophy, Dilated Cardiomyopathy, Heart Failure

In brief

This study will have significant impact on muscular dystrophy patients as it promotes early screening for heart disease. With early identification, beneficial medical therapy can be started sooner, resulting in restoring and maintaining normal heart function. This is critical to the survival of these patients. We have reported previously that heart failure in all patients may have common mechanisms, the "final common pathway". Heart failure is a significant health problem with 5 million people in the US carrying the diagnosis and accounting for 12-15 million office visits and 6.5 million hospital days per year. The number of deaths from heart failure continues to increase. The data from this study could impact patients worldwide with heart failure by offering new insight into an ever-growing disease population and lead to significant changes in how they are currently treated.

Key facts

Study ID

NCT00518817

Run by

Baylor College of Medicine

People needed

60

Starts

2007-08-01

Expected to finish

2009-08-01

Last updated by the study team

2007-08-21

Who can join

Age: 0 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients with the diagnosis of muscular dystrophy.

You may not qualify if…

• Patients that do not carry the diagnosis of muscular dystrophy.

Where it is running

• Texas Children's Hospital — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.